Results 261 to 270 of about 219,275 (300)
Some of the next articles are maybe not open access.

NEW SYNTHETIC ANTIFUNGAL AGENTS

International Journal of Dermatology, 1964
New antifungal agents of the aromatic disulphide and sulphenamide type have been investigated by chemosynthesis.
F, GIALDI, R, PONCI, P, CACCIALANZA
openaire   +2 more sources

Antifungal Agents

2023
Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi, like humans, are eukaryotic organisms and there are a limited number of selective targets that can be exploited for antifungal drug development.
Estefanía Butassi   +2 more
openaire   +1 more source

Investigational Antifungal Agents

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
Several new antifungal agents, including novel compounds in familiar classes and entirely new classes targeting previously untapped mechanisms, are in various stages of the drug development process. Many new triazole antifungal agents are being studied, including voriconazole, posaconazole, and ravuconazole.
openaire   +2 more sources

TOPICAL ANTIFUNGAL AGENTS

Obstetrics and Gynecology Clinics of North America, 1992
Current knowledge of fungal cell architecture and biochemistry allows limited understanding of the mode of action of presently available topical antifungal agents. Nystatin, first introduced in the 1950s for treatment of vulvovaginal candidiasis, has been surpassed by the imidazoles and triazoles as the first choice of treatment for vulvovaginal ...
openaire   +2 more sources

Newer antifungal agents

Expert Review of Anti-infective Therapy, 2011
The frequency and spectrum of fungal infections have been increasing steadily over the last several decades. The reason for this increase may be explained by the increase in the number of immunocompromised patients due to malignancies, AIDS, invasive surgical procedures and transplantation.
openaire   +2 more sources

New antifungal agents

Clinical Microbiology Newsletter, 1982
For more than two decades, amphotericin B has been the single broad-spectrum agent for the treatment of systemic mycoses. Amphotericin B is not always effective, must be given parenterally, and is associated with a host of adverse reactions. Despite amphotericin B toxicity, until recently the systemic mycoses did not rate enough attention to prompt a ...
openaire   +2 more sources

Antifungal Agents

Annals of Internal Medicine, 1979
G, Rapi, P, Cocchi
openaire   +2 more sources

ANTIFUNGAL AGENTS

2009
Andreas H. Groll, Thomas J. Walsh
openaire   +2 more sources

Tackling the emerging threat of antifungal resistance to human health

Nature Reviews Microbiology, 2022
Matthew C Fisher   +2 more
exaly  

Home - About - Disclaimer - Privacy